Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF MEDICAL OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 69,922 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,497 · Balance 68,120 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,624 · Balance 69,744 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,750 · Balance 71,494 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,457 · Balance 73,951 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,029 · Balance 69,922 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 6,700 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 6,700 · Balance 6,700 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,371 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 2,457 · Balance 7,371 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,500 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,750 · Balance 3,500 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,624 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,624 · Balance 1,624 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,497 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 26,750 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 26,750 · Balance 26,750 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · derivative · entry 11 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 2,497 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · derivative · entry 10 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,624 Underlying: Class A Ordinary Share · 1,624 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · derivative · entry 9 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Class A Ordinary Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · derivative · entry 8 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,371 Underlying: Class A Ordinary Share · 2,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 1, 2025. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 26,750 | $0.00 Strike: $79.28 | $0.00 |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · derivative · entry 7 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,750 Underlying: Class A Ordinary Share · 26,750 shares Expires 2036-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · derivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,700 Underlying: Class A Ordinary Share · 6,700 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 4,029 | $79.28 | $319,419.12 |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · nonDerivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,922 Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,457 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,624 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 20:43 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,497 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001741533-26-000010 · form4-09032026_080907.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 58,424 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001741533-26-000008 · form4-05052026_080527.xml · derivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,670 Underlying: Class A Ordinary Share · 58,424 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 21,097 | $54.04 | $1,140,081.88 |
DisclosureSEC source: 0001741533-26-000008 · form4-05052026_080527.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,623 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $53.765 and $54.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 37,327 | $53.52 | $1,997,741.04 |
DisclosureSEC source: 0001741533-26-000008 · form4-05052026_080527.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,720 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $52.765 and $53.76. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:54 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 58,424 | $10.36 | $605,272.64 |
DisclosureSEC source: 0001741533-26-000008 · form4-05052026_080527.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000006 · form4-04082026_080454.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 2,497 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 1,208 | $48.94 | $59,119.52 |
DisclosureSEC source: 0001741533-26-000006 · form4-04082026_080454.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,623 Read SEC document |
| April 07, 2026 Filed Apr 8, 2026 20:41 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,497 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001741533-26-000006 · form4-04082026_080454.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000004 · form4-04032026_080425.xml · derivative · entry 8 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,371 Underlying: Class A Ordinary Share · 2,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. F8 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000004 · form4-04032026_080425.xml · derivative · entry 7 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,500 Underlying: Class A Ordinary Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000004 · form4-04032026_080425.xml · derivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,624 Underlying: Class A Ordinary Share · 1,624 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantPerformance Share Unit · Derivative | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000004 · form4-04032026_080425.xml · derivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,400 Underlying: Class A Ordinary Share · 13,400 shares Expires not disclosed F4 · derivative.exercise_price: Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee F5 · derivative.exercise_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. F5 · derivative.expiration_date: Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001741533-26-000004 · form4-04032026_080425.xml · derivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,700 Underlying: Class A Ordinary Share · 6,700 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 26,750 | $0.00 Strike: $48.13 | $0.00 |
DisclosureSEC source: 0001741533-26-000004 · form4-04032026_080425.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,750 Underlying: Class A Ordinary Share · 26,750 shares Expires 2036-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 2,821 | $48.13 | $135,774.73 |
DisclosureSEC source: 0001741533-26-000004 · form4-04032026_080425.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,334 Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 5,831 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001741533-26-000004 · form4-04032026_080425.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 40,000 | $0.00 Strike: $10.36 | $0.00 |
DisclosureSEC source: 0001741533-26-000002 · form4-03042026_090352.xml · derivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,424 Underlying: Class A Ordinary Share · 40,000 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. F5 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 5,714 | $45.92 | $262,386.88 |
DisclosureSEC source: 0001741533-26-000002 · form4-03042026_090352.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,324 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.56 and $46.09. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 22,223 | $44.88 | $997,368.24 |
DisclosureSEC source: 0001741533-26-000002 · form4-03042026_090352.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,038 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.555 and $45.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 12,063 | $44.20 | $533,184.60 |
DisclosureSEC source: 0001741533-26-000002 · form4-03042026_090352.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,261 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.555 and $44.55. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 40,000 | $10.36 | $414,400.00 |
DisclosureSEC source: 0001741533-26-000002 · form4-03042026_090352.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on November 18, 2025. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 46,000 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001741533-25-000003 · form4-11042025_091113.xml · derivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 46,000 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 30, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 36,542 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001741533-25-000003 · form4-11042025_091113.xml · derivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 36,542 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 30, 2025. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 82,542 | $37.14 | $3,065,609.88 |
DisclosureSEC source: 0001741533-25-000003 · form4-11042025_091113.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,324 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 30, 2025. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $36.80 and $37.675. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 46,000 | $8.83 | $406,180.00 |
DisclosureSEC source: 0001741533-25-000003 · form4-11042025_091113.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 30, 2025. Read SEC document |
| October 31, 2025 Filed Nov 4, 2025 21:36 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 36,542 | $3.80 | $138,859.60 |
DisclosureSEC source: 0001741533-25-000003 · form4-11042025_091113.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on July 30, 2025. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,725 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · derivative · entry 12 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 1,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021. Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 835 | $34.28 | $28,623.80 |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · nonDerivative · entry 6 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,324 Read SEC document |
| September 02, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · nonDerivative · entry 5 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · derivative · entry 11 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,497 Underlying: Class A Ordinary Share · 2,498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · derivative · entry 10 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,248 Underlying: Class A Ordinary Share · 1,624 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · derivative · entry 9 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Class A Ordinary Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2024. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 39,364 | $0.00 Strike: $33.49 | $0.00 |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · derivative · entry 8 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,364 Underlying: Class A Ordinary Share · 39,364 shares Expires 2035-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,828 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · derivative · entry 7 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,828 Underlying: Class A Ordinary Share · 9,828 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 2,841 | $33.49 | $95,145.09 |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · nonDerivative · entry 4 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,434 Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,498 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · nonDerivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,624 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,777 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:48 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023555 · form4-09032025_080906.xml · nonDerivative · entry 1 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 29,325 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-25-021346 · form4-08082025_040802.xml · derivative · entry 3 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,542 Underlying: Class A Ordinary Share · 29,325 shares Expires 2027-06-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 29,325 | $32.55 | $954,528.75 |
DisclosureSEC source: 0001415889-25-021346 · form4-08082025_040802.xml · nonDerivative · entry 2 Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,403 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 16, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.13 and $33.08. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.